Web1.43 “ Potelligent ® Technology ” means BioWa’s proprietary technology directly relating to the use of the cells which produce Antibodies with enhanced ADCC activity by reducing the amount of fucose linked to the carbohydrate chain (“ Potelligent ® Cells ”), including (i) Potelligent ® Cells; (ii) ***; (iii) protein expression, production or … Webusing POTELLIGENT technology (BioWa, Princeton, NJ), which generated an afucosylated mAb. It was hypothesized that GSK2831781 would differentially deplete tissue-resident effector pathogenic T cells with relatively high LAG-3 expres-sion (over lymphocytes expressing low or no LAG-3), impact

Shintaro Hasegawa - Executive Director, Head of Alliance

Web30 Jul 2013 · POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® … brazosport community health network

Expression Technologies Lonza

Web8 Apr 2024 · PDF Multiple Myeloma (MM) remains a difficult to treat disease mainly due to its biological heterogeneity, of which we are more and more knowledgeable... Find, read and cite all the research ... Web25 Sep 2013 · POTELLIGENT technology has the ability to create 100% fucose-free monoclonal antibodies . Creation of the new host-cell line that combines POTELLIGENT … WebPotelligent technology, belonging to Kyowa Hakko Kirin company, and later licensed to Lonza, was employed to develop the FUT8 knockout CHO cell line by gene targeting … brazosport contractor safety council